JP4612417B2 - 眼の遺伝子治療 - Google Patents

眼の遺伝子治療 Download PDF

Info

Publication number
JP4612417B2
JP4612417B2 JP2004532124A JP2004532124A JP4612417B2 JP 4612417 B2 JP4612417 B2 JP 4612417B2 JP 2004532124 A JP2004532124 A JP 2004532124A JP 2004532124 A JP2004532124 A JP 2004532124A JP 4612417 B2 JP4612417 B2 JP 4612417B2
Authority
JP
Japan
Prior art keywords
endostatin
pharmaceutical composition
individual
vector
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004532124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516112A (ja
JP2006516112A5 (cg-RX-API-DMAC10.html
Inventor
ピーター アンソニー カンポチアロ，
マイケル カレコ，
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4612417(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2006516112A publication Critical patent/JP2006516112A/ja
Publication of JP2006516112A5 publication Critical patent/JP2006516112A5/ja
Application granted granted Critical
Publication of JP4612417B2 publication Critical patent/JP4612417B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2004532124A 2002-08-28 2003-08-27 眼の遺伝子治療 Expired - Fee Related JP4612417B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40647002P 2002-08-28 2002-08-28
PCT/EP2003/009497 WO2004020469A2 (en) 2002-08-28 2003-08-27 Ocular gene therapy

Publications (3)

Publication Number Publication Date
JP2006516112A JP2006516112A (ja) 2006-06-22
JP2006516112A5 JP2006516112A5 (cg-RX-API-DMAC10.html) 2010-06-24
JP4612417B2 true JP4612417B2 (ja) 2011-01-12

Family

ID=31978303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004532124A Expired - Fee Related JP4612417B2 (ja) 2002-08-28 2003-08-27 眼の遺伝子治療

Country Status (11)

Country Link
US (1) US20070104684A1 (cg-RX-API-DMAC10.html)
EP (1) EP1534751B1 (cg-RX-API-DMAC10.html)
JP (1) JP4612417B2 (cg-RX-API-DMAC10.html)
CN (2) CN100526332C (cg-RX-API-DMAC10.html)
AT (1) ATE464321T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003258675B2 (cg-RX-API-DMAC10.html)
CA (1) CA2496820A1 (cg-RX-API-DMAC10.html)
DE (1) DE60332122D1 (cg-RX-API-DMAC10.html)
IL (1) IL166950A (cg-RX-API-DMAC10.html)
NZ (1) NZ538958A (cg-RX-API-DMAC10.html)
WO (1) WO2004020469A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174861B1 (en) 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
ATE298371T1 (de) * 1997-09-24 2005-07-15 Univ California Nicht-primaten lentivirale vektoren und verpackungssysteme
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
AU2001295193A1 (en) * 2000-05-01 2001-11-12 Novartis Ag Vectors for ocular transduction and use thereof for genetic therapy
AU2001272932A1 (en) * 2000-06-02 2001-12-17 Entremed, Inc Angiostatin and endostatin binding proteins and methods of use
US20020086007A1 (en) * 2000-10-13 2002-07-04 Sim Kim Lee Angiogenesis-inhibiting peptides and proteins and methods of use
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
WO2003066810A2 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20060251621A1 (en) * 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy

Also Published As

Publication number Publication date
EP1534751B1 (en) 2010-04-14
ATE464321T1 (de) 2010-04-15
HK1077306A1 (en) 2006-02-10
EP1534751A2 (en) 2005-06-01
CN101637611A (zh) 2010-02-03
JP2006516112A (ja) 2006-06-22
WO2004020469A2 (en) 2004-03-11
DE60332122D1 (de) 2010-05-27
IL166950A (en) 2011-04-28
WO2004020469A3 (en) 2004-04-29
CN1708513A (zh) 2005-12-14
NZ538958A (en) 2006-09-29
AU2003258675B2 (en) 2009-03-26
US20070104684A1 (en) 2007-05-10
CA2496820A1 (en) 2004-03-11
AU2003258675A1 (en) 2004-03-19
CN100526332C (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
US8338384B2 (en) Method for treating ocular neovascularization
US7989426B2 (en) Selective induction of apoptosis to treat ocular disease by expression of PEDF
US20070098692A1 (en) Materials and methods for treating ocular-related disorders
JP2002502608A (ja) 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
WO2002026827A1 (en) Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US20100172871A1 (en) Muller Cell Specific Gene Therapy
US20090018100A1 (en) Materials and methods for treating ocular-related disorders
US20060251621A1 (en) Ocular gene therapy
JP3920928B2 (ja) 移植片拒絶反応の防止法および普遍的遺伝子治療宿主細胞の生産法
AU780634C (en) Gene Therapy for treating ocular-related disorders
Kreppel et al. Long-term transgene expression in the RPE after gene transfer with a high-capacity adenoviral vector
EP1534751B1 (en) Ocular gene therapy
HK1077306B (en) Ocular gene therapy
RU2846105C1 (ru) Аденоассоциированный вирус для доставки kh902 (конберцепта) и его применения
JP7179010B2 (ja) 血管新生阻害剤としてのｃ型レクチンであるレベセチン
KR20230092954A (ko) Plvap를 유효성분으로 포함하는 망막 또는 맥락막 질환의 예방 또는 치료용 약학적 조성물
CN118599910A (zh) 一种构建原发性开角型青光眼非人灵长类动物模型的方法
COTLIER et al. Gene Therapy for Genetic and Acquired Retinal Diseases
AU2005202935A1 (en) Gene therapy for treating ocular-related disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091022

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20091022

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20091022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100309

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100917

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101015

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131022

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4612417

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees